COVID Coronavirus vaccine update: Seven Indian pharma companies race to develop COVID-19 vaccine

By: |
New Delhi | Updated: Jul 19, 2020 3:34 PM

COVID Coronavirus vaccine update, India, WHO, USA, Oxford latest news: COVAXIN is being developed by ICMR, Bharat Biotech, ICMR, and NIV, Pune. Zydus Cadila has also begun Phase I trial for its vaccine.

COVID Coronavirus vaccine, COVID Coronavirus vaccine update, COVID Coronavirus vaccine in India, COVID Coronavirus vaccine WHO, COVID Coronavirus vaccine India update, COVID Coronavirus vaccine name, COVID Coronavirus vaccine India latest updateCOVID Coronavirus vaccine update, India, WHO, USA, Oxford latest news: Oxford researchers have revealed that they might have a breakthrough in their endeavour to produce a COVID-19 vaccine.. (Representative image by Reuters)

COVID Coronavirus vaccine update, India, WHO, USA, Oxford latest news: At least seven Indian pharma companies are working to develop a vaccine against coronavirus as they join global efforts to find a preventive to check the spread of the deadly virus that has already infected more than 14 million globally, PTI reported. Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India.

The human clinical trials for Covaxin, a vaccine candidate for COVID-19 being developed by Bharat Biotech has been initiated across the country in 375 volunteers, PTI quoted the company sources as saying. “India’s first indigenous COVID-19 vaccine Covaxin initiated phase-1 clinical trials across the country on 15th July 2020. This is a randomised, double-blind, placebo-controlled clinical trial in 375 volunteers in India,” the sources said.

As far as clinical trials are concerned, “double-blind means neither patient nor researcher knows who is getting a placebo and who is getting the treatment. The Drugs Controller General of India (DCGI) had permitted two vaccines — one developed by the Bharat Biotech International Limited in collaboration with the Indian Council of Medical Research and another one by ZydusCadila Healthcare Ltd to go in for the first and second phase of human clinical trials.

There are two Indian vaccine candidates that have undergone successful toxicity studies in rats, mice and rabbits and this data was submitted to the DCGI, following which both got clearance to start an early phase human trials earlier this month, ICMR Director General Dr Balram Bhargava had said.

Earlier, it was reported that India’s COVAXIN produced by the Indian Council of Medical Research (ICMR), Bharat Biotech, and National Institute of Virology, Pune have started human trials for the country’s first indigenous COVID Coronavirus vaccine at PGI Rohtak today. “Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse efforts,” Haryana Health Minister Anil Vij said.

In a major breakthrough for India’s indigenous potential COVID Coronavirus vaccine candidate, its developer Zydus Cadila has received nod from Mexico’s regulatory authority Cofepris to conduct human trials in that country. Zydus Cadila has received approval for clinical trials with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHepTM’. The company has revealed that the human trials will be “an open-label, randomized, comparator-controlled study… to evaluate safety, efficacy and tolerability in patients with COVID-19”.

Around the world, human trials of potential COVID Coronavirus vaccine candidates developed by Russia, US’ Moderna, and UK’s Oxford-AstraZeneca have shown positive results so far.

Coronavirus vaccine UK Oxford AstraZeneca

University of Oxford researchers have revealed that they might have a breakthrough in their endeavour to produce a COVID-19 vaccine. The announcement has come after the University of Oxford team discovered that the jab could provide “double protection” against the deadly coronavirus following early-stage human trials. The human trials of Oxford-AstraZeneca showed that the dose of vaccine has successfully managed to produce both antibodies and “killer T-cells” in the receiver’s body. The results are promising because separate studies have indicated that antibodies may fade away within months while T-cells can stay in circulation for years.

The University of Oxford in collaboration with global biopharmaceutical firm AstraZeneca has been developing a potential coronavirus vaccine candidate ChAdOx1 nCoV-19. The vaccine candidate has entered the Phase III Human trials. While Phase 1 trial of the potential coronavirus vaccine has shown promising results, the complete data will be published on July 20.

Coronavirus vaccine Russia

Russia has said that its “World’s first coronavirus covid19 vaccine” is ‘safe’. The Defence Ministry of that country has revealed that all the volunteers who were part of the human trials did not show “serious adverse events, health complaints, complications or side effects”. The defence ministry has revealed it expects clinical trials of the potential coronavirus vaccine will be fully completed by the end of July. Officials in Moscow earlier said that the “civil distribution” of the coronavirus vaccine could begin by mid-August and mass production in September. Russia has also planned to produce 30 million doses of the potential COVID19 vaccine domestically in 2020, with the potential to manufacture a further 170 million abroad, as per the Reuters report.

COVID Coronavirus vaccine in India

India’s two indigenous coronavirus vaccine candidates have entered the human trials phase. COVAXIN is being developed by ICMR, Bharat Biotech, ICMR, and NIV, Pune. Zydus Cadila has also begun Phase I trial for its vaccine.

Coronavirus vaccine USA Moderna

US-based Moderna has been working on a potential coronavirus vaccine candidate known as mRNA-1273 in collaboration with Kaiser Permanente Washinton Health Research Institute. The phase I trials of Moderna began on March 16 and Moderna was the first organization to commence the clinical trial of the potential coronavirus vaccine candidate. An interim analysis has revealed that an immune response has been generated in participants of phase I clinical trials, as per a report published in the New England Journal of Medicine. Moderna will begin its Phase III trials on July 27.

COVID Coronavirus vaccine WHO

World Health Organization (WHO) has revealed that more than 150 potential vaccines for coronavirus are at different stages of development. So, around 23 vaccines have managed to reach the human trials phase. Meanwhile, state heads of eight countries – Canada, Tunisia, Spain, New Zealand, South Korea, Ethiopia, Sweden, and South Africa have sought fair distribution of Coronavirus vaccine when it is developed.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1How many health workers were infected or died during COVID duty? No data maintained by Central govt
2Bars in Andhra Pradesh to be re-opened from September 19
3Coronavirus vaccine: EU seals second coronavirus vaccine deal